Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

October 21, 2021

Study Completion Date

February 8, 2022

Conditions

Interstitial Lung Disease

Interventions

BIOLOGICAL

AD-214

AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

OTHER

Placebo

Trial Locations (2)

Scientia Clinical Research Ltd, Randwick

CMAX Clinical Research Pty Ltd, Adelaide